

Jay Kozlowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6199850/publications.pdf>

Version: 2024-02-01

13
papers

135
citations

1478505

6
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

320
citing authors

#	ARTICLE	IF	CITATIONS
1	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQ12 Experience. <i>Thrombosis Research</i> , 2014, 134, 294-299.	1.7	35
2	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 283-288.	2.1	22
3	Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. <i>Implementation Science</i> , 2017, 12, 87.	6.9	18
4	Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQ12). <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 10-14.	2.1	13
5	Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQ12). <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 171-176.	2.1	12
6	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. <i>Blood Advances</i> , 2017, 1, 2536-2540.	5.2	7
7	Periprocedural Bridging Anticoagulation: Measuring the Impact of a Clinical Trial on Care Delivery. <i>American Journal of Medicine</i> , 2019, 132, 109.e1-109.e7.	1.5	7
8	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 566-572.	2.1	6
9	Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2025-2030.	3.8	6
10	The changing characteristics of atrial fibrillation patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 488-493.	2.1	4
11	Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients. <i>Journal of Pharmacy Practice</i> , 2023, 36, 542-547.	1.0	2
12	Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events. <i>Vascular Medicine</i> , 2022, 27, 382-384.	1.5	2
13	Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. <i>American Journal of Cardiology</i> , 2021, 159, 100-106.	1.6	1